フォレチニブ
フォレチニブ 物理性質
- 融点 :
- >98°C (dec.)
- 沸点 :
- 828.5±65.0 °C(Predicted)
- 比重(密度) :
- 1.372
- 貯蔵温度 :
- Sealed in dry,Store in freezer, under -20°C
- 溶解性:
- DMSO（微量）、エタノール（微量）
- 酸解離定数(Pka):
- 13.14±0.70(Predicted)
- 外見 :
- 黄色い粉。
- 色:
- 淡い黄色から黄色
- CAS データベース:
- 849217-64-7
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQJ-1646 |
フォレチニブ
Foretinib |
849217-64-7 |
100mg |
￥175000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQJ-1646 |
Foretinib |
849217-64-7 |
250mg |
￥260000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQJ-1646 |
フォレチニブ
Foretinib |
849217-64-7 |
1g |
￥650000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01MAS090437 |
N-(3-Fluoro-4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)-oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
849217-64-7 |
250mg |
￥1912700 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01MAS125243 |
フォレチニブ
Foretinib |
849217-64-7 |
1g |
￥4065700 |
2023-06-01 |
購入 |
フォレチニブ 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬, 血管新生阻害薬, 受容体チロシンキナーゼ阻害薬
説明
Foretinib is a multikinase inhibitor that targets MET and VEGFR2 and also exhibits an inhibitory effect against KIT, Flt-3, PDGFRb, and Tie-2.
使用
Foretinib (GSK1363089) is an ATP-competitive inhibitor of hepatocyte growth factor (HGF) and Vascular endothelial growth factor (VEGF) Receptor Tyrosine Kinases.
臨床応用
Foretinib has also shown to be effective against ROS1 mutations especially when acquired with crizotinib resistance. A clinical trial investigating the dosing and safety profile of combining foretinib and erlotinib was designed for advanced pretreated NSCLC patients.
フォレチニブ 上流と下流の製品情報
原材料
準備製品
フォレチニブ 生産企業
Global( 175)Suppliers
849217-64-7(フォレチニブ)キーワード:
- 849217-64-7
- GSK 1363089
- N-[3-Fluoro-4-[[6-(methyloxy)-7-[[3-(morpholin-4-yl)propyl]oxy]quinolin-4-yl]oxy]phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
- N-[3-Fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
- XL-880,Foretinib
- XL880(GSK1363089)
- FORETINIB GLAXOSMITHKLINE PAPILLARY RENAL CELL CARCINOMA PHASE IIRSCH. TRIANGLE PARK, NC (SEE ALSO HEAD/NECK) (888) 825-5249
- foretinib
N1-{3-fluoro-4-[(6-(Methyloxy)-7-{[3-(4-Morpholinyl)propyl]oxy}-4-quinolinyl)oxy]phenyl}-N1'-(4-fluorophenyl)-1,1-cyclopropanedicarboxaMide
- Foretinib (GSK1363089, XL880)
- GSK089
- GSK1363089; FORETINIB; EXEL-2880
- Foretinib, Free Base
- EXEL-2880/XL-880
- N-(3-fluoro-4-(6-Methoxy-7-(3-Morpholinopropoxy)quinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxaMide
- N1'-[3-fluoro-4-[[6-Methoxy-7-(3-Morpholinopropoxy)-4-quinolyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxaMide
- GSK1363089/foretinib
- N-(3-Fluoro-4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)-oxy)phenyl)-N-(4-fluorophenyl)cyc
- Foretinib (GSK1363089)
- N-[3-Fluoro-4-[[6-(methyloxy)-7-[[3-(morpholin-4-yl)propyl]oxy]quinolin-4-yl]oxy]phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1
- Foretinib, >=98%
- Foretinib (XL-880)
- N-(3-Fluoro-4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)-oxy)phenyl)-N-(4-fluorophenyl)
- 1-N'-[3-FLUORO-4-({6-METHOXY-7-[3-(MORPHOLIN-4-YL)PROPOXY]QUINOLIN-4-YL}OXY)PHENYL]-1-N-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE
- Foretinib (XL880,EXEL-2880)
- XL880 (GSK1363089, Foretinib, EXEL-2880)
- XL-880;EXEL-2880;XL 880
- XL-880;GSK089;EXEL-2880;XL 880;GSK-089; GSK 1363089; GSK-1363089
- XL880; XL 880; XL-880; GSK1363089; GSK 1363089; GSK-1363089; GSK089; EXEL2880; FORETINIB.
- 1,1-Cyclopropanedicarboxamide, N-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl)-
- Foretinib (GSK1363089) USP/EP/BP
- N1'-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinol...
- フォレチニブ
- N'1-[3-フルオロ-4-({6-メトキシ-7-[3-(モルホリン-4-イル)プロポキシ]キノリン-4-イル}オキシ)フェニル]-N1-(4-フルオロフェニル)シクロプロパン-1,1-ジカルボキサミド
- ホレチニブ
- N-(4-フルオロフェニル)-N′-[3-フルオロ-4-[6-メトキシ-7-(3-モルホリノプロポキシ)-4-キノリルオキシ]フェニル]シクロプロパン-1,1-ジカルボアミド